"Phenylpropanolamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.
Below are MeSH descriptors whose meaning is more general than "Phenylpropanolamine".
Below are MeSH descriptors whose meaning is more specific than "Phenylpropanolamine".
This graph shows the total number of publications written about "Phenylpropanolamine" by people in this website by year, and whether "Phenylpropanolamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Phenylpropanolamine" by people in Profiles.
Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010 May; 75(5):1144-8.
Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep; 10(13):2181-94.
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005 Jun; 192(6):1849-54; discussion 1854-5.
Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug; 15(4):243-8.
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.